Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2004-08-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 32
- Registration Number
- NCT00003413
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00002604
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Cleveland, Cleveland, Ohio, United States
🇺🇸Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Radiation Therapy in Treating Patients With Brain Cancer
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 212
- Registration Number
- NCT00002620
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹Kaiser Franz Josef Hospital, Vienna (Wien), Austria
🇬🇧Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom
Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 200
- Registration Number
- NCT00002545
- Locations
- 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸Penn State Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2017-07-27
- Target Recruit Count
- 110
- Registration Number
- NCT00086879
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇳🇱Medisch Centrum Haaglanden, 's-Gravenhage, Netherlands
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2013-06-04
- Target Recruit Count
- 147
- Registration Number
- NCT00005613
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT00003996
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Wichita, Wichita, Kansas, United States
🇺🇸CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00002676
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00003401
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00003399
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.